EcoDrugPlus

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSOTSG00005007263
Gene Symbol: MAPK9
3 Cross references
165 Possible Orthologues:

Mitogen-Activated Protein Kinase 9-Like

Ensembl ID : ENSOTSG00005017814
Gene Symbol: LOC112220751
2 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSOTSG00005000083
Gene Symbol: MAP2K1
1 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2a

Ensembl ID : ENSOTSG00005004423
Gene Symbol: MAP2K2A
1 Cross references
207 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2b

Ensembl ID : ENSOTSG00005046079
Gene Symbol: MAP2K2B
1 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2b

Ensembl ID : ENSOTSG00005016323
Gene Symbol: MAP2K2B
1 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSOTSG00005017726
Gene Symbol: MAP3K1
3 Cross references
155 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSOTSG00005009215
Gene Symbol: MAP3K1
3 Cross references
154 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSOTSG00005035313
Gene Symbol: MAP3K10
1 Cross references
176 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSOTSG00005022368
Gene Symbol: MAP3K10
1 Cross references
176 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSOTSG00005008279
Gene Symbol: MAP3K11
1 Cross references
176 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOTSG00005040521
Gene Symbol: MAP3K12
1 Cross references
179 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).